Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea

References

• Jang ES. The Nationwide Seroprevalence of Anti-HCV Is Decreasing from 2009 to 2015 in South Korea. in Paper presented at: The liver week 2017; Incheon, Korea. 2017.
   Google Scholar
• Kim DY, Kim IH, Jeong S-H, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int. 2013;33(4):586–594.,
   PubMed Web of Science ®Google Scholar
• Ki M, Choi HY, Kim K-A, et al. Healthcare costs for chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data. Gut Liver. 2017;11(6):835–842.
   PubMed Web of Science ®Google Scholar
• Shon C, Choi H-Y, Shim J-J, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis. 2016;69(1):18–27.
   PubMed Web of Science ®Google Scholar
• Korean Association for the Study of the, L. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22(1):76–139.
   PubMed Web of Science ®Google Scholar
• Nam JY, Jang ES, Kim YS, et al. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective, Multicenter Cohort Study. in American Association for the Study of Liver Disease. 2018. San Francisco, California, United States. Available from: https://pubmed.ncbi.nlm.nih.gov/31158950/
   Google Scholar
• WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018. World Health Organization: Geneva.
   Google Scholar
• Kim DY, Han K-H, Jun B, et al. Estimating the cost-effectiveness of one-time screening and treatment for Hepatitis C in Korea. PLoS One. 2017;12(1):e0167770.
   PubMed Web of Science ®Google Scholar
• Kim K-A, Chung W, Choi HY, et al. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population. Liver Int. 2019;39(1):60–69.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544–563.
   PubMed Web of Science ®Google Scholar
• Population and Housing Census. Statistics Korea; 2018 [cited 30 Mar 2019]. Available from: http://kostat.go.kr/portal/eng/pressReleases/8/7/index.board
   Google Scholar
• Seong MH, Kil H, Kim YS, et al. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol. 2013;85(10):1724–1733.
   PubMed Web of Science ®Google Scholar
• Ahn H-R, Cho S-B, Chung IJ, et al. Socioeconomic differences in self- and family awareness of viral hepatitis status among carriers of hepatitis B or C in rural Korea. Am J Infect Control. 2018;46(3):328–332.
   PubMed Web of Science ®Google Scholar
• Lee CH, Shin HP, Lee JI, et al. Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody. Clin Mol Hepatol. 2013;19(4):376–381.
   PubMedGoogle Scholar
• Service KNHI. National health statistical yearbook. 2015. Korea: Wonju.
   Google Scholar
• Nam JY, Jang ES, Kim YS, et al. Epidemiological and clinical characteristics of Hepatitis C virus infection in South Korea from 2007 to 2017: a prospective multicenter cohort study. Gut Liver. 2019;14(2):207–217.
   Web of Science ®Google Scholar
• Liles EG, Perrin N, Rosales AG, et al. Change to FIT increased CRC screening rates: evaluation of a US screening outreach program. Am J Manag Care. 2012;18(10):588–595.
   PubMed Web of Science ®Google Scholar
• Ahn SH, et al. Korean patients with genotype 1 and 2 HCV infection achievedover 97 % sustained virologic response following 12 weeksof ledipasvir sofosbuvir or sofosbuvir plus ribavirin. Hepatology International. 2015;9(1):1–391.
   Google Scholar
• Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat. 2016;23(5):358–365.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354–369.
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068.
   PubMed Web of Science ®Google Scholar
• Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–426.
   PubMed Web of Science ®Google Scholar
• Thein H-H, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–431.
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):i–xii 1-210.
   PubMed Web of Science ®Google Scholar
• Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2):518–527.
   PubMed Web of Science ®Google Scholar
• Ishida H, Yotsuyanagi H. Study of the cost-effectiveness of the standard treatment for chronic hepatitis C. Ministry of Health Labour and Welfare; 2013 [cited 30 Mar 2019]. Available from: https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B
   Google Scholar
• Okanoue T, Minami M, Makiyama A, et al. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S89–S91.
   PubMedGoogle Scholar
• Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396–405.
   PubMed Web of Science ®Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5_Part_1):329–337.
   PubMed Web of Science ®Google Scholar
• Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52(5):652–657.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Terajima K, Aoyagi Y, et al. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008;215(1):33–42.
   PubMed Web of Science ®Google Scholar
• Sugimori H, Ikeda T, Hirao T, et al. Health and Labour Sciences Research Grant, Research on medical economic evaluation of various countermeasures related to viral liver disease, Research report Study on utility value of hepatitis (in Japanese). 2013.
   Google Scholar
• Younossi ZM, Stepanova M, Nader F, et al. The patient’s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42(3):286–295.
   PubMed Web of Science ®Google Scholar
• Life Tables for Korea. Statistics Korea. 2018 [cited 30 Mar 2019]. Available from: http://kostat.go.kr/portal/eng/pressReleases/8/6/index.board
   Google Scholar
• Hira S. Health care medical care costs 2018. 2018. Korea: Wonju.
   Google Scholar
• Kim do Y, Yoon KT, Kim W, et al. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine (Baltimore). 2016;95(30):e3896.
   PubMed Web of Science ®Google Scholar
• Organization WH. Choosing interventions that are cost-effective. 2014. [30 March 2019].
   Google Scholar
• Kim J, Haacker M, Keshavjee S, et al. Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea. BMJ Glob Health. 2019;4(3):e001441.
   PubMed Web of Science ®Google Scholar
• Kim DD, Hutton DW, Raouf AA, et al. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015;10(3):296–317.
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Yuan Y, et al. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology. 2013;58(1):54–64.
   PubMed Web of Science ®Google Scholar
• Eckman MH, Talal AH, Gordon SC, et al. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013;56(10):1382–1393.
   PubMed Web of Science ®Google Scholar
• McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55(5):1344–1355.
   PubMed Web of Science ®Google Scholar
• Coffin PO, Scott JD, Golden MR, et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54(9):1259–1271.
   PubMed Web of Science ®Google Scholar
• Moyer VA, Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–357.
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Huneau A, Verleene A, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69(4):785–792.
   PubMed Web of Science ®Google Scholar
• Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380(21):2041–2050.
   PubMed Web of Science ®Google Scholar
• Cho B, Lee CM. Current situation of national health screening systems in Korea. J Korean Med Assoc. 2011;54(7):666–669.
   Web of Science ®Google Scholar
• National Health Screening Statistical Yearbook. NHIC. 2015 [cited 2019 Mar 30]. Available from: http://kostat.go.kr/
   Google Scholar
• Younossi ZM, Chan HLY, Dan YY, et al. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25(3):228–235.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. Liver Int. 2018;38(7):1179–1187.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Tanaka A, Eguchi Y, et al. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat. 2018;25(8):945–951.
   PubMed Web of Science ®Google Scholar
• Jang ES, Kim YS, Kim K-A, et al. Factors Associated with health-related quality of life in korean patients with chronic hepatitis C infection using the SF-36 and EQ-5D. Gut Liver. 2018;12(4):440–448.
   PubMed Web of Science ®Google Scholar
• Brook RA, Kleinman NL, Su J, et al. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011;17(10):657–664.
   PubMed Web of Science ®Google Scholar
• Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436–442.
   PubMed Web of Science ®Google Scholar